Characteristic | N = 100 |
---|---|
Age, mean ± SD | 55.03 ± 11.20 |
Gender, male, % | 74 |
Body mass index (kg/m2), median (IQR) | 18.83 (17.78–23.11) |
< 18.5 (underweight), N (%) | 31 |
18.5–22.9 (normal weight), N (%) | 44 |
23.0–24.9 (overweight), N (%) | 6 |
≥ 25.0 (obesity), N (%) | 19 |
Viral status, % | |
HBV/HCV/HBV + HCV/none | 58/8/0/34 |
Child–Pugh classification, % | |
A/B/C | 60/32/8 |
BCLC stage, % | |
A/B/C/D | 7/25/59/9 |
ECOG PS, % | |
0/1/2/3 | 32/41/22/5 |
LCSGJ TNM stage, % | |
1/2/3/4 | 0/21/32/47 |
AJCC TNM stage 8th edition, % | |
1/2/3/4 | 20/5/32/43 |
JIS score, % | |
1/2/3/4/5 | 18/23/31/23/5 |
Treatment, % | |
Curative (liver transplant, resection, PEIT, RFA) | 0 |
Palliative (TACE, sorafenib) | 65 |
Supportive (end-stage life support) | 35 |
Alcohol consumption, % | |
Yes/no | 8/72 |
Clinical signs and symptoms, % | |
Malaise, nausea, vomiting/hematemesis or melena | 76/11 |
Abdominal pain/weight loss | 68/80 |
Jaundice/ascites | 25/32 |
Hepatomegaly/splenomegaly | 92/30 |
Tumour diameter, mean ± SD (cm) | 12.05 ± 4.97 |
Type of tumour, % | |
Nodular/diffuse | 65/35 |
Single/multiple | 30/70 |